Logo

WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B

Share this

WuXi Vaccines Signs Twenty Years Manufacturing Agreement with Global Vaccine Leaders for $3B

Shots:

  • Wuxi Vaccines to establish new manufacturing facility which includes drug substance manufacturing (DS)- drug product manufacturing (DP)- manufacture science and technology labs (MS&T) as well as quality control labs (QC)
  • The facility will develop and manufacture partner’s vaccine therapy for the global market. The new facility is expected to be operational in 2022
  • Additionally- in Nov’2019- Wuxi invests $240M to establish a new vaccine manufacturing facility in Ireland. Wuxi biologics will provide its global partners with a robust and premier-quality supply chain network to develop high-quality vaccines protecting humans globally

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bio Spectrum Asia


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions